Article
Oncology
Chun-Yao Huang, Hui-Li Huang, Chou-Chin Lan, Yi-Chih Huang, Yao-Kuang Wu
Summary: This study retrospectively investigated the survival benefits and safety profile of afatinib plus ramucirumab in treatment-naive patients with EGFR-mutated non-small cell lung cancer. The results showed that afatinib plus ramucirumab could improve the PFS of patients with EGFR-positive NSCLC at a predictable safety profile.
Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Jia Li Low, Yiqing Huang, Kenneth Sooi, Yvonne Ang, Zhi Yao Chan, Katie Spencer, Anand Devaprasath Jeyasekharan, Raghav Sundar, Boon Cher Goh, Ross Soo, Wei Peng Yong
Summary: The study found that there was no significant difference in survival outcomes, toxicity, and costs between 100 mg and 200 mg doses of pembrolizumab in the treatment of advanced non-small cell lung cancer. The lower dose of 100 mg showed potential cost savings without compromising efficacy, suggesting the need for further investigation through a randomized trial.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Multidisciplinary Sciences
Yoshitaka Saito, Shinya Tamaki, Daisuke Hirate, Shinya Takada, Kenta Takahashi, Yoh Takekuma, Jun Sakakibara-Konishi, Yasushi Shimizu, Ichiro Kinoshita, Mitsuru Sugawara
Summary: Baseline anemia and prophylactic G-CSF administration are factors associated with a reduced risk of treatment reduction in patients receiving DOC + RAM for NSCLC treatment.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Katherine Minichiello, Liza C. Villaruz, Bryan Faller, Tareq Al Baghdadi, Susan Hines, Leah Everhart, Louise Highleyman, Vassiliki Papadimitrakopoulou, David R. Gandara, Karen Kelly, Roy S. Herbst
Summary: This randomized phase II trial demonstrated that the combination of ramucirumab and pembrolizumab significantly improved overall survival in patients with advanced non-small-cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy. The safety profile of this combination therapy was consistent with the known toxicities of both drugs.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Moto Yaga, Takayuki Shiroyama, Haruhiko Hirata, Kaori Oya, Yoshito Takeda, Atsushi Kumanogoh
Summary: Diagnosing newly emerged abnormal lung shadows during treatment with immune checkpoint inhibitors can be challenging. Clinicians should be aware of this rare but severe phenomenon in patients undergoing immune checkpoint inhibitor therapy.
CLINICAL LUNG CANCER
(2022)
Article
Multidisciplinary Sciences
Daichi Fujimoto, Satoru Miura, Keisuke Tomii, Hiromitsu Sumikawa, Kenichi Yoshimura, Kazushige Wakuda, Yuko Oya, Toshihide Yokoyama, Takashi Kijima, Tetsuhiko Asao, Motohiro Tamiya, Atsushi Nakamura, Hiroshige Yoshioka, Takaaki Tokito, Shuji Murakami, Akihiro Tamiya, Hiroshi Yokouchi, Satoshi Watanabe, Ou Yamaguchi, Ryotaro Morinaga, Takayuki Jodai, Kentaro Ito, Yoshimasa Shiraishi, Yoshihito Kogure, Ryota Shibaki, Nobuyuki Yamamoto
Summary: This study investigated the characteristics of pneumonitis associated with chemo-immunotherapy. The imaging features of pneumonitis were mainly an organizing pneumonia pattern. The severity of pneumonitis, diffuse alveolar damage pattern, and extent of lung disease were significantly associated with worsening respiratory status.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Chuan Zhang, Jiaxu Zhang, Jing Tan, Panwen Tian, Weimin Li
Summary: The study conducted a systematic review and pooled analysis on the cost-effectiveness of pembrolizumab strategies for NSCLC treatment. The results showed that pembrolizumab is cost-effective in the United States and Switzerland, but not in other countries such as China, France, the UK, and Singapore.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Valsamo Anagnostou, Cheryl Ho, Garth Nicholas, Rosalyn Anne Juergens, Adrian Sacher, Andrea S. Fung, Paul Wheatley-Price, Scott A. Laurie, Benjamin Levy, Julie R. Brahmer, Archana Balan, Noushin Niknafs, Egor Avrutin, Liting Zhu, Mark Sausen, Penelope A. Bradbury, Jill O'Donnell-Tormey, Pierre Olivier Gaudreau, Keyue Ding, Janet Dancey
Summary: Circulating tumor DNA (ctDNA) is useful for capturing primary resistance to immunotherapy in lung cancer. The BR.36 trial demonstrates the correlation between ctDNA response and radiologic response, and identifies molecular response as a predictor of longer progression-free and overall survival.
Article
Medicine, General & Internal
Isa Mambetsariev, Leonidas Arvanitis, Jeremy Fricke, Rebecca Pharaon, Angel R. Baroz, Michelle Afkhami, Marianna Koczywas, Erminia Massarelli, Ravi Salgia
Summary: EGFR-mutated lung adenocarcinoma patients can transform into SCLC after receiving TKI therapy. This study evaluated 9 patients who underwent such transformation and found that they had unique clinical, molecular, and histological characteristics at different time points. The findings are important for understanding the molecular heterogeneity and clinical outcomes of this EGFR TKI resistance subtype.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Yasmina Sirgi, Rebecca Krochmal, Christine M. Fleury, Margaret Holmes, Christine A. Dewitt, Michael Cardis, Chul Kim
Summary: Immune checkpoint inhibitor therapy has revolutionized the treatment approach for various cancers, including non-small cell lung cancer. However, this therapy can give rise to a wide range of immune-related adverse effects, necessitating prompt identification and management. As the use of immune checkpoint inhibitors becomes more prevalent, rare immune-related adverse effects are increasingly being recognized. This case report presents a patient with advanced non-small cell lung cancer who developed pembrolizumab-associated sarcoidosis involving multiple organs. A multidisciplinary approach to management led to timely diagnosis and treatment, resulting in symptom improvement. This case raises awareness about the rare side effect of sarcoidosis associated with pembrolizumab.
CLINICAL LUNG CANCER
(2022)
Article
Biochemistry & Molecular Biology
Meina Wang, Roy S. Herbst, Chris Boshoff
Summary: Over the past two decades, molecular targeted therapies and immunotherapies have significantly improved outcomes for non-small-cell lung cancer (NSCLC), but the majority of advanced NSCLCs eventually become resistant. The future challenge lies in the application of predictive biomarkers for patient stratification in order to better manage NSCLC.
Article
Medicine, General & Internal
Yuko Kubo, Kimiteru Ito, Yutaka Fujiwara, Tatsuya Yoshida, Masahiko Kusumoto
Summary: This case report highlights a rare occurrence of SAPHO syndrome mimicking bone metastases during treatment with pembrolizumab, emphasizing the importance for physicians to be vigilant about the possibility of SAPHO syndrome during immunotherapy.
FRONTIERS IN MEDICINE
(2021)
Article
Oncology
Yasmin Leshem, Yardenna Dolev, Nava Siegelmann-Danieli, Sarah Sharman Moser, Lior Apter, Gabriel Chodick, Alla Nikolaevski-Berlin, Sivan Shamai, Ofer Merimsky, Ido Wolf
Summary: This study evaluated the impact of diabetes mellitus (DM) on the efficacy of pembrolizumab in treating metastatic non-small cell lung cancer (NSCLC). The results showed that patients with DM had shorter progression-free survival and overall survival, especially when treated with pembrolizumab alone. The study suggests that immunotherapy may be less beneficial in NSCLC patients with diabetes.
Article
Oncology
Mehmet Altan, Janet Tu, Denai R. Milton, Bulent Yilmaz, Yanyan Tian, Frank V. Fossella, Frank E. Mott, George R. Blumenschein, Bettzy Stephen, Daniel D. Karp, Funda Meric-Bernstam, John V. Heymach, Aung Naing
Summary: This study aimed to assess the safety and early efficacy of pembrolizumab and selinexor combination therapy in the treatment of metastatic non-small cell lung cancer (mNSCLC). The results showed that the combination therapy had good antitumor activity, and it was also effective in patients who had previously received anti-PD-1/PD-L1 therapy.
Article
Pharmacology & Pharmacy
Irene Y. Chong, Ian Chau
Summary: Stomach cancer is a global health problem that requires multimodality treatment for locally advanced cases. The use of chemoradiotherapy after D2 gastrectomy has not been supported by the best evidence so far. Ongoing trials with translational endpoints will provide important guidance for the use of chemoradiotherapy in the neoadjuvant setting. Radiotherapy can effectively alleviate symptoms of advanced gastric cancer and Stereotactic Body Radiotherapy shows promise in controlling oligometastatic liver disease in some patients.
CURRENT OPINION IN PHARMACOLOGY
(2023)
Article
Oncology
David K. Lau, Maria Aresu, Timothy Planche, Amina Tran, Retchel Lazaro-Alcausi, Julie Duncan, Shannon Kidd, Susan Cromarty, Ruwaida Begum, Isma Rana, Su Li, Ali Abdulnabi Mohamed, Irene Monahan, David J. Clark, Nicholas Eckersley, Henry M. Staines, Elisabetta Groppelli, Sanjeev Krishna, Martin Mayora-Neto, Nigel Temperton, Charlotte Fribbens, David Watkins, Naureen Starling, Ian Chau, David Cunningham, Sheela Rao
Summary: The study evaluated the prevalence of neutralizing antibodies in 152 gastrointestinal cancer patients receiving chemotherapy after SARS-CoV-2 vaccination, finding that despite the immunosuppressive effects of chemotherapy, two doses of vaccines can still induce a protective immune response in patients undergoing treatment.
Article
Oncology
Avani Athauda, Matthew Nankivell, Rupert Langer, Susan Pritchard, Ruth E. Langley, Katharina von Loga, Naureen Starling, Ian Chau, David Cunningham, Heike I. Grabsch
Summary: No definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following neoadjuvant chemotherapy and the impact on survival.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Eric Van Cutsem, Maria di Bartolomeo, Elizabeth Smyth, Ian Chau, Haeseong Park, Salvatore Siena, Sara Lonardi, Zev A. Wainberg, Jaffer Ajani, Joseph Chao, Yelena Janjigian, Amy Qin, Jasmeet Singh, Ferdous Barlaskar, Yoshinori Kawaguchi, Geoffrey Ku
Summary: The DESTINY-Gastric02 trial is a phase 2 study evaluating the efficacy of trastuzumab deruxtecan in HER2-positive advanced gastric and gastro-oesophageal junction cancer. The results demonstrate clinically meaningful response rates, supporting its use as second-line therapy for these patients.
Letter
Oncology
Dima El-Sharkawi, Amit Sud, Catherine Prodger, Jahanzaib Khwaja, Rohan Shotton, Brian Hanley, Victoria Peacock, Ying Ying Peng, Anita Arasaretnam, Sarkhara Sharma, Frances Aldridge, Bhupinder Sharma, Andrew Wotherspoon, Betty Cheung, Corinne De Lord, Rosalynd Johnston, Shireen Kassam, Ruth Pettengel, Kim Linton, Paul Greaves, Lucy Cook, Kikkeri N. Naresh, Kate Cwynarski, Toby A. Eyre, Ian Chau, David Cunningham, Sunil Iyengar
BLOOD CANCER JOURNAL
(2023)
Editorial Material
Oncology
Ian Chau
Meeting Abstract
Oncology
Neil McCafferty, Caroline Fong, Louise J. Barber, Andrew Woolston, Dimitrios Kleftogiannis, Taqia Rana, Susan Cromarty, Shannon Kidd, Ruwaida Begum, Ian Chau, Naureen Starling, David Cunningham, Marco Gerlinger
Meeting Abstract
Oncology
Marco Gerlinger, Anderley Gordon, Louise J. Barber, Georgios Laliotis, Avani Athauda, Benjamin Challoner, Andrew Woolston, Sonia Mansukhani, Matt Dunstan, Nikoletta Petrou, Komel Khabra, Retchel Lazaro-Alcausi, Richard Crux, Victoria Borja, Ruwaida Begum, Isma Rana, Charuta Palsuledesai, Meenakshi Malhotra, Minetta Liu, Adham Jurdi, Shruti Sharma, Sheela Rao, Sacheen Kumar, David Cunningham, Ian Chau, Naureen Starling, M. Asif Chaudry
Article
Oncology
Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Andrea Lampis, Laura Satchwell, Clare Peckitt, Caroline Fong, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Fribbens, Sheela Rao, Naureen Starling, Ian Chau, David Cunningham, Nicola Valeri
Summary: This study identified miR-148a-3p as a potential biomarker for trastuzumab-based therapy in HER2-positive oesophago-gastric cancer patients. The results showed that the expression level of miR-148a-3p is associated with patient survival and progression rates.
FRONTIERS IN ONCOLOGY
(2023)
Meeting Abstract
Biophysics
Shima Ismail, Farheen Mir, Chloe Anthias, Sandra Easdale, Mike Potter, Mark Ethell, Carlos Arias, Bhupinder Sharma, David Cunningham, Ian Chau, Sunil Iyengar, Dima El-Sharkawi, Emma Nicholson
BONE MARROW TRANSPLANTATION
(2023)
Meeting Abstract
Oncology
Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Caroline Fong, Laura Satchwell, Clare Peckitt, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Victoria Fribbens, David J. Watkins, Sheela Rao, Ian Chau, Naureen Starling, David Cunningham, Nicola Valeri
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Mairead Geraldine McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Olusesan Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sothi Sharmila, Alan Anthoney, Alkesh Patel, Angela Lamarca, Richard Hubner, Juan W. Valle
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Susanna Slater, Annette Bryant, Maria Aresu, Ruwaida Begum, Hsiang-Chi Chen, Clare Peckitt, Retchel Lazaro-Alcausi, Paul Carter, Gayathri Anandappa, Shelize Khakoo, Graham Branagan, Nicol George, Muti Abulafi, Sarah Duff, Nicholas West, Leslie Bucheit, Thereasa A. Rich, Ian Chau, Naureen Starling, David Cunningham
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Avani Athauda, Tatiany Silveira, Thomas Lund, Katharina von Loga, Benjamin Challoner, Isma Rana, Janet Thomas, Naureen Starling, Ian Chau, Sheela Rao, David J. Watkins, David Cunningham, Marco Gerlinger
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Anderley Gordon, Benjamin Challoner, Avani Athauda, Andrew Woolston, Sonia Mansukhani, Matt Dunstan, Nikoletta Petrou, Komel Khabra, Retchel Lazaro-Alcausi, Richard Crux, Victoria Borja, Ruwaida Begum, Isma Rana, Sheela Rao, Sacheen Kumar, David Cunningham, Ian Chau, Naureen Starling, M. Asif Chaudry, Marco Gerlinger
JOURNAL OF CLINICAL ONCOLOGY
(2023)